A Portable Device for Rapid and Highly Sensitive Diagnostics

When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.

Over the past several years, microfluidic devices have shown extraordinary potential in the area of diagnostics. They are composed of silicone rubber with minuscule channels the width of a hair. Microfluidic devices, and can rapidly detect a number of different biomarkers in very small quantities of blood.

At EPFL, a new type of microfluidic platform has come out of the Laboratory of Biological Network Characterization (LBNC), headed by Sebastian Maerkl. It is a portable device that runs on battery power and is completely self-sustained. It operates seamlessly with inexpensive microscopes and provides very high levels of accuracy and detection. The platform, which is described in a recent ACS Nano article, can quantify up to 16 different molecules - or biomarkers - in a tiny amount of blood (less than 0.005 milliliters). The biomarkers are usually enzymes, proteins, hormones or metabolites and the concentration of these molecules in the blood provides precise information on the patient's health condition.

Two detection readouts in one platform
The device is unique in that it is composed of both analog and digital detection mechanisms, while conventional devices hitherto only integrated one or the other. Digital detection is highly sensitive and can detect the presence of a single biomarker. However, it is less effective when the concentration of biomarkers is too high, due to signal saturation. Analog measurements, on the other hand, function best at higher biomarker concentrations. Using these two detection mechanisms simultaneously, the composition of a drop of blood can be thoroughly analyzed in a short amount of time. The analysis provides precious medical information: it could help doctors make an early diagnosis or determine the stage of a disease.

Initial testing has been successfully carried out on a sample containing anti-Ebola antibodies, which indicate the presence of the virus in both symptomatic and asymptomatic patients. The device could potentially work with a large number of other protein biomarkers and molecules.

No need to pre-treat blood samples
There is more good news. Researchers at EPFL found that they could load the blood sample directly onto the device and perform on-chip biomarker quantitation without requiring any sample pre-treatment. "For researchers, it is quite interesting to be able to avoid having to separate the blood," said Francesco Piraino, the article's lead author. Blood plasma separation requires centrifuges, large volume samples and a long processing time.

For diagnoses in resource-limited regions
Says Piraino: "The platform will lead the development of new kinds of tests to meet the increasing demand for on-site diagnostic testing. It will prove very useful for medical staff working in resource-limited regions." The device could, for example, be used to monitor endemic, epidemic, and pandemic disease outbreaks.

Francesco Piraino, Francesca Volpetti, Craig Watson, and Sebastian J. Maerkl
A Digital-Analog Microfluidic Platform for Patient-Centric Multiplexed Biomarker Diagnostics of Ultralow Volume Samples
ACS Nano 2016 10 (1), 1699-1710, DOI: 10.1021/acsnano.5b07939

Most Popular Now

Zebra Announces Regulatory Approval of i…

Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in...

Mind-Controlled Device Helps Stroke Pati…

Stroke patients who learned to use their minds to open and close a device fitted over their paralyzed hands gained some control over their hands, according to a new study...

Philips and Illumina Team Up with Navica…

Royal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems...

NHS Organisations to Access IMS MAXIMS C…

Award-winning electronic patient record (EPR) provider IMS MAXIMS has announced the availability of its cloud services on the latest iteration of the UK Government's G Cloud Framework. NHS organisations looking...

Boehringer Ingelheim Builds Digital Lab …

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together...

Artificial Intelligence to Assist in the…

The University of Tampere and TAYS (Tampere University Hospital) Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart...

Anyone can Become More Curious. Is that …

Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described...

EC Open Call FETOPEN-01-2016-2017: FET-O…

The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas...

Home Monitoring of Blood Sugar Did Not I…

Self-monitoring of blood glucose levels in patients with type 2 diabetes who are not treated with insulin did not improve glycemic control or health-related quality of life after one year...

Call for Applications: 2017 Lyfebulb-Nov…

For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives...

New Cellular Imaging Paves Way for Cance…

Researchers at the Universities of York and Leiden have pioneered a technique which uses florescent imaging to track the actions of key enzymes in cancer, genetic disorders and kidney disease...

UK PACS Win for Carestream Announced

West Hertfordshire Hospitals NHS Trust (West Herts) located in the South East of the UK and Carestream have signed and exchanged contracts to replace the Trust's existing PACS with a...